(Q38189848)

30 August 2017

1 reference

title

Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013. (English)

1 reference

30 August 2017

Peter Norman

1

1 reference

30 August 2017

language of work or name

English

0 references

publication date

20 February 2014

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

published in

1 reference

30 August 2017

volume

24

1 reference

30 August 2017

issue

5

1 reference

30 August 2017

page(s)

573-595

1 reference

Structure and function of Syk protein-tyrosine kinase

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Targeting Syk as a treatment for allergic and autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Protein tyrosine kinase, syk: a key player in phagocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Protein tyrosine kinase Syk in mast cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

ZAP70 expression in regulatory T cells in allergic rhinitis: effect of immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Proximal protein tyrosine kinases in immunoreceptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

The SYK tyrosine kinase: a crucial player in diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Therapeutic prospect of Syk inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Spleen tyrosine kinases: biology, therapeutic targets and drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

The Syk kinase as a therapeutic target in leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Basophils and autoreactive IgE in the pathogenesis of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.890184

10.1517/13543776.2014.890184

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference